Sean D Sullivan
Biographic Data
| ID | 3927538 |
|---|---|
| NAME | Sean D Sullivan |
| GIVEN NAMES | Sean D |
| FAMILY NAME | Sullivan |
| SIGNATURE | SULLIVAN S D |
| AFFILIATIONS | University of Washington |
| VERIFIED | No |
| TOTAL WORKS | 16 |
| TOTAL CITATIONS | 3 |
| AUTHOR COUNT | 16 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 1994 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 1 |
Value-Based Pricing of US Prescription Drugs: Estimated Savings Using Reports From the Institute for Clinical and Economic Review
This cross-sectional study estimates how annual US drug spending would change if prices for prescription drugs were set at the value-based price
Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe
Transformative cell and gene therapies have now launched worldwide, and many potentially curative cell and gene therapies are in development, offering the prospect of significant health gains for patients. Access to these therapies depend on decisions made by health technology assessment (HTA) and payer organizations. We sought to describe the emerging cell and gene therapies market access landscape by analyzing 17 US commercial payer medical pol…
Economic Value of Greater Access to Bariatric Procedures for Patients With Severe Obesity and Diabetes
OBJECTIVE: Designing optimal insurance is important to ensure access to care for individuals that are most likely to benefit. We examined the potential impact of lowering patient cost-sharing for bariatric procedures. METHODS: After defining 10 subgroups by body mass index (BMI) and type 2 diabetes mellitus (T2DM), we analyzed the National Health and Nutrition Examination Survey datasets to estimate the prevalence of each subgroup. The MarketScan…
Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures
BACKGROUND: Value-based benefit design has been suggested as an effective approach to managing the high cost of pharmaceuticals in health insurance markets. Premera Blue Cross, a large regional health plan, implemented a value-based formulary (VBF) for pharmaceuticals in 2010 that explicitly used cost-effectiveness analysis (CEA) to inform medication copayments. OBJECTIVE OF THE STUDY: The objective of the study was to determine the impact of the…
Sedative Hypnotic Medication Use and the Risk of Motor Vehicle Crash
Objectives. We sought to estimate the association between sedative hypnotic use and motor vehicle crash risk. Methods. We conducted a new user cohort study of 409 171 adults in an integrated health care system. Health plan data were linked to driver license and collision records. Participants were aged 21 years or older, licensed to drive in Washington State, had at least 1 year of continuous enrollment between 2003 and 2008, and were followed un…
Medical Costs Associated with Use of Systemic Therapy in Adults with Colorectal Cancer
BACKGROUND: New cytotoxic agents and regimens, as well as immunotherapeutics, have recently been introduced for treatment of colorectal cancer (CRC). OBJECTIVE: To identify the patient-related and clinical and treatment-related factors associated with higher total health care expenditures in newly diagnosed patients with CRC who are receiving systemic therapy (biologic or chemotherapy) from a commercially insured population. METHODS: A longitudin…
Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes
Medicaid Prior Authorization and Controlled-Release Oxycodone
BACKGROUND: Since its introduction in 1996, controlled-release (CR) oxycodone use has increased steadily despite its high cost. To control use and expenditures, many Medicaid programs have implemented CR oxycodone prior authorization (PA) policies. Few studies evaluate Medicaid policies or compare lenient and strict policies in multiple states. OBJECTIVE: To estimate the impact of PA on CR oxycodone use by Medicaid beneficiaries. DESIGN: Secondar…
A Forensic Evaluation of the National Emphysema Treatment Trial Using the Expected Value of Information Approach
BACKGROUND/RATIONALE: Expected value of information (EVI) analyses allow researchers to estimate the returns to conducting research. We used EVI techniques to estimate the value of the National Emphysema Treatment Trial (NETT), a multicenter randomized trial of lung-volume-reduction surgery (LVRS) versus medical therapy (MT) for patients with severe emphysema, then compared that result to the trial cost. METHODS: We gathered information on costs …
Trends and Geographic Variation of Opiate Medication Use in State Medicaid Fee-For-Service Programs, 1996 to 2002
BACKGROUND: Although studies have documented hospital and surgical service geographic variability, prescription use geographic variability is largely unknown. Opiate pain medications are widely used, particularly because the promulgation of clinical guidelines promoting aggressive pain treatment. This study describes temporal and interstate variability in aggregate prescription opiate medication use within U.S. Medicaid programs. METHODS: A datas…
Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies
PURPOSE: To provide a practical quantitative tool for appraising the quality of cost-effectiveness (CE) studies. METHODS: A committee comprising [corrected] of health economists selected a set of criteria for the instrument from an item pool. Data collected with a conjoint analysis survey on 120 international health economists were used to estimate weights for each criterion with a random effects regression model. To validate the grading system, …
Modeling the Cost and Outcomes of Pharmacist-Prescribed Emergency Contraception
Objectives. This study investigated the effect on the risk and cost of unintended pregnancies of emergency contraceptive pills obtained directly from a pharmacist. Methods. We used a decision model to compare outcomes for private and public payers following unprotected intercourse from. Results. Obtaining emergency contraceptive pills from a pharmacy, compared with obtaining them from a physician or clinic, resulted in a $158 (95% confidence inte…
On Estimating Costs for Economic Evaluation in Failure Time Studies
Only recently have attempts been made to adjust for the bias censoring can impart on economic estimates based on data obtained during a clinical trial. This article reviews a suggested approach that adopts techniques developed for adjusting for the effect of censoring on estimation of failure time. The authors show that this approach does not provide unbiased estimation and explain the reason why this is the case
Willingness to pay for antihypertensive care: Evidence from a staff-model HMO
Firm behavior in the U.S. market for factor VIII: A need for policy
The Hospital Response to Medicare??s Prospective Payment System: An Econometric Model of Blue Cross and Blue Shield Plans
This paper presents an empirical analysis of the impact that resulted from phase-in of Medicare's Prospective Payment System (PPS) on hospital utilization and payments for the Blue Cross and Blue Shield (BCBS) plans. A pooled cross-sectional time series econometric model was specified and estimated using quarterly hospital utilization and payments of the BCBS plans over the period 1980 to 1987. The results indicate that the implementation of PPS …
Firm behavior in the U.S. market for factor VIII: A need for policy
The Hospital Response to Medicare??s Prospective Payment System: An Econometric Model of Blue Cross and Blue Shield Plans
This paper presents an empirical analysis of the impact that resulted from phase-in of Medicare's Prospective Payment System (PPS) on hospital utilization and payments for the Blue Cross and Blue Shield (BCBS) plans. A pooled cross-sectional time series econometric model was specified and estimated using quarterly hospital utilization and payments of the BCBS plans over the period 1980 to 1987. The results indicate that the implementation of PPS …
Willingness to pay for antihypertensive care: Evidence from a staff-model HMO
On Estimating Costs for Economic Evaluation in Failure Time Studies
Only recently have attempts been made to adjust for the bias censoring can impart on economic estimates based on data obtained during a clinical trial. This article reviews a suggested approach that adopts techniques developed for adjusting for the effect of censoring on estimation of failure time. The authors show that this approach does not provide unbiased estimation and explain the reason why this is the case
Modeling the Cost and Outcomes of Pharmacist-Prescribed Emergency Contraception
Objectives. This study investigated the effect on the risk and cost of unintended pregnancies of emergency contraceptive pills obtained directly from a pharmacist. Methods. We used a decision model to compare outcomes for private and public payers following unprotected intercourse from. Results. Obtaining emergency contraceptive pills from a pharmacy, compared with obtaining them from a physician or clinic, resulted in a $158 (95% confidence inte…
Development and Validation of a Grading System for the Quality of Cost-Effectiveness Studies
PURPOSE: To provide a practical quantitative tool for appraising the quality of cost-effectiveness (CE) studies. METHODS: A committee comprising [corrected] of health economists selected a set of criteria for the instrument from an item pool. Data collected with a conjoint analysis survey on 120 international health economists were used to estimate weights for each criterion with a random effects regression model. To validate the grading system, …
Trends and Geographic Variation of Opiate Medication Use in State Medicaid Fee-For-Service Programs, 1996 to 2002
BACKGROUND: Although studies have documented hospital and surgical service geographic variability, prescription use geographic variability is largely unknown. Opiate pain medications are widely used, particularly because the promulgation of clinical guidelines promoting aggressive pain treatment. This study describes temporal and interstate variability in aggregate prescription opiate medication use within U.S. Medicaid programs. METHODS: A datas…
Medicaid Prior Authorization and Controlled-Release Oxycodone
BACKGROUND: Since its introduction in 1996, controlled-release (CR) oxycodone use has increased steadily despite its high cost. To control use and expenditures, many Medicaid programs have implemented CR oxycodone prior authorization (PA) policies. Few studies evaluate Medicaid policies or compare lenient and strict policies in multiple states. OBJECTIVE: To estimate the impact of PA on CR oxycodone use by Medicaid beneficiaries. DESIGN: Secondar…
A Forensic Evaluation of the National Emphysema Treatment Trial Using the Expected Value of Information Approach
BACKGROUND/RATIONALE: Expected value of information (EVI) analyses allow researchers to estimate the returns to conducting research. We used EVI techniques to estimate the value of the National Emphysema Treatment Trial (NETT), a multicenter randomized trial of lung-volume-reduction surgery (LVRS) versus medical therapy (MT) for patients with severe emphysema, then compared that result to the trial cost. METHODS: We gathered information on costs …
Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes
Medical Costs Associated with Use of Systemic Therapy in Adults with Colorectal Cancer
BACKGROUND: New cytotoxic agents and regimens, as well as immunotherapeutics, have recently been introduced for treatment of colorectal cancer (CRC). OBJECTIVE: To identify the patient-related and clinical and treatment-related factors associated with higher total health care expenditures in newly diagnosed patients with CRC who are receiving systemic therapy (biologic or chemotherapy) from a commercially insured population. METHODS: A longitudin…
Sedative Hypnotic Medication Use and the Risk of Motor Vehicle Crash
Objectives. We sought to estimate the association between sedative hypnotic use and motor vehicle crash risk. Methods. We conducted a new user cohort study of 409 171 adults in an integrated health care system. Health plan data were linked to driver license and collision records. Participants were aged 21 years or older, licensed to drive in Washington State, had at least 1 year of continuous enrollment between 2003 and 2008, and were followed un…
Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures
BACKGROUND: Value-based benefit design has been suggested as an effective approach to managing the high cost of pharmaceuticals in health insurance markets. Premera Blue Cross, a large regional health plan, implemented a value-based formulary (VBF) for pharmaceuticals in 2010 that explicitly used cost-effectiveness analysis (CEA) to inform medication copayments. OBJECTIVE OF THE STUDY: The objective of the study was to determine the impact of the…
Economic Value of Greater Access to Bariatric Procedures for Patients With Severe Obesity and Diabetes
OBJECTIVE: Designing optimal insurance is important to ensure access to care for individuals that are most likely to benefit. We examined the potential impact of lowering patient cost-sharing for bariatric procedures. METHODS: After defining 10 subgroups by body mass index (BMI) and type 2 diabetes mellitus (T2DM), we analyzed the National Health and Nutrition Examination Survey datasets to estimate the prevalence of each subgroup. The MarketScan…
Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe
Transformative cell and gene therapies have now launched worldwide, and many potentially curative cell and gene therapies are in development, offering the prospect of significant health gains for patients. Access to these therapies depend on decisions made by health technology assessment (HTA) and payer organizations. We sought to describe the emerging cell and gene therapies market access landscape by analyzing 17 US commercial payer medical pol…
Value-Based Pricing of US Prescription Drugs: Estimated Savings Using Reports From the Institute for Clinical and Economic Review
This cross-sectional study estimates how annual US drug spending would change if prices for prescription drugs were set at the value-based price
Medicine (15 works) · Economics (9 works) · Health Systems, Economic Evaluations, Quality of Life (8 works) · Health care (7 works) · Internal Medicine (7 works) · Internal Medicine (7 works) · Healthcare Policy and Management (5 works) · Population (5 works) · Business (4 works) · Econometrics (4 works)